drugset / Trial / NCT04029090

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

NCT04029090

Phase 1 Completed 27 enrolled Shionogi
RandomizedCrossoverDouble-blindOther

Summary

To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)

Timeline

Start
2018-09-18
Primary completion
2018-10-20
Completion
2018-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Edaravone Unknown 60 mg Intravenous
Subject Edaravone Unknown 300 mg Intravenous

Indications

No indication recorded.